Rebecca Melvin, DO
Internal Medicine · Saint Charles, MONPI 1609079409
Payments from drug & device makers
Across 87 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$380
- Lilly USA, LLC$126
- Supernus Pharmaceuticals, Inc.$78
- Amgen$75
- Bayer$70
- Pfizer$68
- plus $906 from 30 others
What the payments were for
- Food & beverage$1,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $380 |
| Lilly USA, LLC | 6 | $126 |
| Supernus Pharmaceuticals, Inc. | 4 | $78 |
| Amgen | 4 | $75 |
| Bayer | 4 | $70 |
| Pfizer | 4 | $68 |
| Sanofi Pasteur Inc. | 3 | $64 |
| Novo Nordisk | 3 | $60 |
| GSK | 4 | $58 |
| Lundbeck LLC | 2 | $57 |
| Corcept Therapeutics | 2 | $50 |
| Exact Sciences | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Neos Therapeutics, LP | 2 | $40 |
| Tris Pharma Inc | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Merck | 2 | $32 |
| Cranial Technologies, Inc | 2 | $31 |
| Globus Medical | 1 | $29 |
| Radius Health, Inc. | 1 | $26 |
| Nevro Corp. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Novartis | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $16 |
| AstraZeneca | 1 | $13 |
| UCB, Inc. | 1 | $13 |
How this compares
$1,703 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $31,080 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,578 |
| JardianceEmpagliflozin | 16 | $16,323 |
| FarxigaDapagliflozin Propanediol | 11 | $8,583 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,753 |
| Atorvastatin Calcium | 134 | $1,766 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,250 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $896 |
| Omeprazole | 38 | $725 |
| Gabapentin | 59 | $648 |
| Levothyroxine Sodium | 77 | $642 |
| Amlodipine Besylate | 102 | $570 |
| Metoprolol Succinate | 48 | $562 |
| Pregabalin | 18 | $486 |
| Fluticasone Propionate | 32 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $31,08042 claims |
| GSKTrelegy Ellipta | $58 | $17,57821 claims |
| Boehringer IngelheimJardiance | $21 | $16,32316 claims |
| AstraZenecaFarxiga | $13 | $8,58311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Charles
- Justin SteinkampSaint Charles$139K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.